GenBio Participates in BIO-Europe 2026 for International Collaboration

ALISO VIEJO, CA, UNITED STATES, October 6, 2026 /CourierPR/ -- GenBio Inc., a biotechnology company focused on developing compounds inspired by nature, has announced its participation in BIO-Europe 2026, marking the company’s second international partnering conference. The event, which will take place from November 9 to 11, 2026, at Koelnmesse in Cologne, Germany, is described by its organizer as Europe’s largest and longest-running partnering conference for the global biotechnology and biopharmaceutical industry.

GenBio’s participation in BIO-Europe 2026 represents the company’s next step in expanding its international business development efforts. The company intends to connect with pharmaceutical and biotechnology companies, investors, and potential development partners to explore opportunities aligned with its scientific programs and corporate strategy. The conference provides a platform for GenBio to introduce its nature-inspired research platform and discuss potential scientific collaborations, licensing arrangements, asset transactions, and broader strategic opportunities.

GenBio’s development portfolio includes several research programs, such as BlockR™, an anti-inflammatory research program; ResistR™, an antimicrobial resistance research program; and ProlifR™, an emerging oncology research program. These programs remain investigational and depend on further research and validation.

According to Todd D. Sonoga, Director and Chief Marketing Officer of GenBio Inc., the company’s participation in BIO-Europe 2026 is part of its ongoing efforts to build relationships across international markets while advancing its scientific work and intellectual property strategy.

BIO-Europe is expected to attract a community of more than 5,800 participants from over 3,200 companies across more than 60 countries. The event brings together biotechnology and pharmaceutical executives, emerging companies, investors, academic researchers, and industry service providers. GenBio’s attendance and partnering discussions do not guarantee any partnership, investment, or transaction.

The company’s participation in BIO-Europe 2026 supports its broader strategy of advancing its programs through scientific research, intellectual property development, and strategic relationships. GenBio seeks to identify potential partners and explore opportunities that could enhance the development and commercialization of its research programs.